{"id":391392,"date":"2020-12-02T03:24:04","date_gmt":"2020-12-02T08:24:04","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391392"},"modified":"2020-12-02T03:24:04","modified_gmt":"2020-12-02T08:24:04","slug":"targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/","title":{"rendered":"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">OSLO, Norway<\/span>, <span class=\"xn-chron\">Dec. 2, 2020<\/span> \/PRNewswire\/ &#8212; <b>Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today present data from its melanoma and mesothelioma trials in an online webcast at <span class=\"xn-chron\">10:00am CET<\/span>.<\/b><\/p>\n<p>With reference to the press release issued <span class=\"xn-chron\">1 December 2020<\/span> (<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2998886-1&amp;h=1146046444&amp;u=https%3A%2F%2Fwww.targovax.com%2Fen%2Ftargovax-announces-impressive-objective-responses-as-well-as-effects-on-non-injected-lesions-in-oncos-102-trial-in-anti-pd1-refractory-melanoma-patients%2F&amp;a=see+link+here\" rel=\"nofollow noopener noreferrer\">see link here<\/a>), Targovax will present data from its phase 1 trial combining ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in patients with advanced, unresectable melanoma who have had disease progression despite treatment with anti-PD1 CPI. <\/p>\n<p>Data from the randomized phase 1\/2 trial of ONCOS-102 in combination with standard-of-care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM), which was released <span class=\"xn-chron\">24 November 2020<\/span> (<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2998886-1&amp;h=3678589437&amp;u=https%3A%2F%2Fwww.targovax.com%2Fen%2Ftargovax-demonstrates-encouraging-survival-data-for-oncos-102-in-mesothelioma%2F&amp;a=see+link+here\" rel=\"nofollow noopener noreferrer\">see link here<\/a>), will also be presented in the webcast. <\/p>\n<p>The webcast starts at <span class=\"xn-chron\">10:00am CET<\/span> and you can join the webcast <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2998886-1&amp;h=1773280806&amp;u=https%3A%2F%2Fchannel.royalcast.com%2Flandingpage%2Fhegnarmedia%2F20201202_5%2F&amp;a=here\" rel=\"nofollow noopener noreferrer\">here<\/a>. It will be possible to ask questions during the presentation. A replay of the webcast will be available in the Investor section under &#8220;Presentations&#8221; after the event.<\/p>\n<p>For further information, please contact:<\/p>\n<p \/>\n<p><span class=\"xn-person\">Renate Birkeli<\/span>, Investor Relations<br \/>Phone: +47 922 61 624<br \/>Email: <a target=\"_blank\" href=\"mailto:renate.birkeli@targovax.com\" rel=\"nofollow noopener noreferrer\">renate.birkeli@targovax.com <\/a><\/p>\n<p \/>\n<p><b>Media enquires: <br \/><\/b><\/p>\n<p><span class=\"xn-person\">Andreas Tinglum<\/span><br \/>Corporate Communications (<span class=\"xn-location\">Norway<\/span>)<br \/>Phone: +47 9300 1773<br \/>Email: <a target=\"_blank\" href=\"mailto:andreas.tinglum@corpcom.no\" rel=\"nofollow noopener noreferrer\">andreas.tinglum@corpcom.no <\/a><\/p>\n<p>IR enquires: <\/p>\n<p \/>\n<p><span class=\"xn-person\">Kim Sutton Golodetz<\/span> &#8211; LHA Investor Relations (US)<br \/>Email: <a target=\"_blank\" href=\"mailto:kgolodetz@lhai.com\" rel=\"nofollow noopener noreferrer\">kgolodetz@lhai.com <\/a><br \/>Phone: +1 212-838-3777<\/p>\n<p \/>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2998886-1&amp;h=721829617&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2998886-1&amp;h=3381452092&amp;u=https%3A%2F%2Fnews.cision.com%2Ftargovax%2Fr%2Ftargovax-asa--invitation-to-online-presentation-at-10-00-cet-2-december%2Cc3247614&amp;a=https%3A%2F%2Fnews.cision.com%2Ftargovax%2Fr%2Ftargovax-asa--invitation-to-online-presentation-at-10-00-cet-2-december%2Cc3247614\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/targovax\/r\/targovax-asa&#8211;invitation-to-online-presentation-at-10-00-cet-2-december,c3247614<\/a><\/p>\n<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december-301183360.html\">http:\/\/www.prnewswire.com\/news-releases\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december-301183360.html<\/a><\/p>\n<p>SOURCE  Targovax<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO09413&amp;Transmission_Id=202012020320PR_NEWS_USPR_____IO09413&amp;DateId=20201202\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire OSLO, Norway, Dec. 2, 2020 \/PRNewswire\/ &#8212; Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today present data from its melanoma and mesothelioma trials in an online webcast at 10:00am CET. With reference to the press release issued 1 December 2020 (see link here), Targovax will present data from its phase 1 trial combining ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in patients with advanced, unresectable melanoma who have had disease progression despite treatment with anti-PD1 CPI. Data from the randomized phase 1\/2 trial of ONCOS-102 in combination with standard-of-care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM), which was released 24 November 2020 (see &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Targovax ASA: Invitation to online presentation at 10:00 CET 2 December&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391392","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Targovax ASA: Invitation to online presentation at 10:00 CET 2 December - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire OSLO, Norway, Dec. 2, 2020 \/PRNewswire\/ &#8212; Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today present data from its melanoma and mesothelioma trials in an online webcast at 10:00am CET. With reference to the press release issued 1 December 2020 (see link here), Targovax will present data from its phase 1 trial combining ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in patients with advanced, unresectable melanoma who have had disease progression despite treatment with anti-PD1 CPI. Data from the randomized phase 1\/2 trial of ONCOS-102 in combination with standard-of-care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM), which was released 24 November 2020 (see &hellip; Continue reading &quot;Targovax ASA: Invitation to online presentation at 10:00 CET 2 December&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T08:24:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December\",\"datePublished\":\"2020-12-02T08:24:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09413&amp;sd=2020-12-02\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/\",\"name\":\"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09413&amp;sd=2020-12-02\",\"datePublished\":\"2020-12-02T08:24:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09413&amp;sd=2020-12-02\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO09413&amp;sd=2020-12-02\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/","og_locale":"en_US","og_type":"article","og_title":"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December - Market Newsdesk","og_description":"PR Newswire OSLO, Norway, Dec. 2, 2020 \/PRNewswire\/ &#8212; Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today present data from its melanoma and mesothelioma trials in an online webcast at 10:00am CET. With reference to the press release issued 1 December 2020 (see link here), Targovax will present data from its phase 1 trial combining ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in patients with advanced, unresectable melanoma who have had disease progression despite treatment with anti-PD1 CPI. Data from the randomized phase 1\/2 trial of ONCOS-102 in combination with standard-of-care (SoC) chemotherapy in patients with malignant pleural mesothelioma (MPM), which was released 24 November 2020 (see &hellip; Continue reading \"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T08:24:04+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December","datePublished":"2020-12-02T08:24:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/","name":"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02","datePublished":"2020-12-02T08:24:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO09413&amp;sd=2020-12-02"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-asa-invitation-to-online-presentation-at-1000-cet-2-december\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Targovax ASA: Invitation to online presentation at 10:00 CET 2 December"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391392"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391392\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}